Related Experiment Video

Updated: May 20, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Synthetic lethality to overcome cancer drug resistance

L Porcelli1, A E Quatrale, P Mantuano

  • 1Clinical Experimental Oncology Laboratory, National Cancer Institute Giovanni Paolo II, Bari, Italy.

Current Medicinal Chemistry
|July 14, 2012
PubMed

Insights

Synthetic lethality enhances anticancer drug efficacy by targeting essential cancer cell genes. This approach helps overcome chemotherapy resistance and guides personalized treatment selection for solid tumors.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Synthetic lethality offers a strategy to improve anticancer drug effectiveness.
  • Understanding gene interdependence is key to developing targeted therapies.
  • Drug resistance to conventional chemotherapy is a significant clinical challenge.

Purpose of the Study:

  • To review the application of synthetic lethality in overcoming chemotherapy resistance in solid tumors.
  • To highlight cellular markers and gene mutations associated with cancer cell viability and drug resistance.
  • To suggest novel molecularly targeted strategies for combating drug resistance.

Main Methods:

  • Literature review of synthetic lethality applications in oncology.
  • Analysis of findings on cellular markers and gene mutations in drug-resistant cancers.
  • Synthesis of information to propose new targeted therapeutic strategies.

Main Results:

  • Synthetic lethality can amplify drug efficacy in anticancer regimens.
  • Specific cellular markers and gene mutations are crucial for cancer cell survival and chemoresistance.
  • Exploiting synthetic lethality can overcome resistance to conventional chemotherapy.

Conclusions:

  • Synthetic lethality is a promising strategy for enhancing cancer treatment.
  • Identifying predictive factors through synthetic lethality aids in selecting effective targeted drugs and combinations.
  • Novel molecularly targeted strategies are needed to address drug resistance in solid tumors.

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...